Kamada's $50M Plasma Deal Validates Its U.S. Collection Hub Strategy
KMDA is trading near its 52-week low of $6.5 (6.3% above the low).
Summary
Kamada announced a three-year, $50 million plasma supply agreement with a leading biopharmaceutical company, with initial sales expected in Q4 2026. The deal validates its plasma collection strategy and is already reflected in existing guidance.
Key Events · M&A and Partnerships · KMDA
-
$50M Plasma Supply Agreement Signed
A three-year agreement to supply normal source plasma to a leading biopharmaceutical company is expected to generate approximately $50 million in revenue over its term.
-
Revenue Contribution and Timing
Initial commercial sales under the agreement are expected to be recorded in the fourth quarter of 2026, and the revenue is included in Kamada's current full-year guidance.
-
Validation of U.S. Collection Centers
The agreement draws on plasma from Kamada's FDA-approved collection centers in Houston and San Antonio, Texas, validating the company's investment in its U.S. plasma collection infrastructure.
-
Strategic Fit with Growth Pillars
The deal supports Kamada's vertical-integration strategy and its goal of driving revenue growth through plasma sales to other manufacturers—one of the company's four primary growth pillars.
Analysis · KMDA · Life Sciences
A three-year, $50 million normal source plasma supply agreement with a leading biopharmaceutical company marks the first major commercial validation of Kamada's investment in its U.S. collection infrastructure. Revenue from the deal is expected to begin flowing in Q4 2026 and is already embedded in the company's full-year guidance, so near-term forecasts remain unchanged—but the contract confirms the viability of the vertical-integration strategy. For a company with a market cap of roughly $407 million, a $50 million revenue stream spread over three years is a meaningful growth contributor, even though the annualized impact is modest relative to total revenue. The agreement also signals that Kamada's Texas collection centers are ramping up on schedule, reinforcing the multi-year revenue growth narrative.
At the time of this filing, KMDA was trading at $6.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $406.7M. The 52-week trading range was $6.50 to $9.35. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.